AbbVie Just Won FDA Approval for a Once-Daily Parkinson's Pill. Here's Why It Matters More Than You Think.
Another potential blockbuster just joined AbbVie's drug portfolio.
Overview
Earlier this week, the U.S. Food and Drug Administration (FDA) approved AbbVie's (NYSE: ABBV) Juvmo (tavapadon). This is a once-daily pill for adults with Parkinson's disease that gives the pharmaceutical giant a new treatment for an ailment affecting more than 10 million people worldwide.
The approval also puts one of the key assets from AbbVie's $8.7 billion acquisition of Cerevel Therapeutics on the market. AbbVie completed that deal in 2024 in an effort to strengthen its neuroscience pipeline, and Juvmo now has a chance to start generating a return on that investment.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.